Cardiotoxicity publications have been increasing at an astounding pace since the 1970s. If there was a time to be bringing a cardioprotective agent with historic clinical efficacy to market, it is now. 2024 is on track to being another massive year for cardiotoxicity research - hopefully publications relating to Zantrene can be in that mix. For the record, publications on FTO is only 4000.
Cardioprotection thread, page-343
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
-0.010(0.66%) |
Mkt cap ! $252.5M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.57 | $1.47 | $198.4K | 131.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 3154 | 3 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.50 |
Change
-0.010 ( 0.66 %) |
||||
| Open | High | Low | Volume | ||
| $1.53 | $1.56 | $1.47 | 18229 | ||
| Last updated 15.53pm 22/05/2024 ? | |||||
| RAC (ASX) Chart |